Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern India

Introduction: Multidrug resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is a leading cause of death in India. To combat this, National TB Elimination Programme, erstwhile RNTCP) has launched “shorter oral bedaquiline (Bdq)-containing MDR/RR-TB regimen” from March 2021 replacing the injectabl...

Full description

Saved in:
Bibliographic Details
Main Authors: Hindol Mondal, Manasi Basu Banerjee, Abheek Das, Somnath Maity
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-07-01
Series:Journal of Advanced Lung Health
Subjects:
Online Access:https://journals.lww.com/10.4103/jalh.jalh_64_24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850083080004435968
author Hindol Mondal
Manasi Basu Banerjee
Abheek Das
Somnath Maity
author_facet Hindol Mondal
Manasi Basu Banerjee
Abheek Das
Somnath Maity
author_sort Hindol Mondal
collection DOAJ
description Introduction: Multidrug resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is a leading cause of death in India. To combat this, National TB Elimination Programme, erstwhile RNTCP) has launched “shorter oral bedaquiline (Bdq)-containing MDR/RR-TB regimen” from March 2021 replacing the injectable containing MDR/RR-TB regimen in a phased manner. Objective: We want to measure the outcome and safety profile of this newly introduced shorter oral Bdq-containing MDR/RR-TB regimen.” Materials and Methods: A prospective observational study was conducted to evaluate the effectiveness and adverse drug reaction (ADR) profile of “Shorter oral Bdq-containing regimen.” After getting approval from the ethics committee, all MDR/RR-TB subjects receiving the regimen from MDR-TB clinic of Malda Medical College were included in the study and followed up. Sociodemographic data and treatment outcome details were evaluated. ADRs were evaluated for causality, severity assessment, and management aspects. Result: Of the total, 96 patients were assessed for eligibility. Sixty-three patients were enrolled (n = 63), followed up and analyzed. 19 (30%) patients were cured while 33 (52.4%) patients more had completed treatment. 6 (9.5%) patients declared as treatment failure. One subject died during treatment. Four patients were lost to follow-up (6.4%). In total, 189 ADRs were reported. Commonly observed ADRs were anorexia (60%), nausea (51%), and weakness (46%). Majority were “possible” category by causality assessment and “mild” in severity assessment. Hepatitis was only severe ADR observed. Conclusion: Success rate and adherence observed with this regimen were encouraging. ADRs were mostly mild and managed symptomatically with regular monitoring in some cases.
format Article
id doaj-art-18100cf27f2f475fbb40597d87d6df7c
institution DOAJ
issn 2772-7165
2772-7173
language English
publishDate 2025-07-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Advanced Lung Health
spelling doaj-art-18100cf27f2f475fbb40597d87d6df7c2025-08-20T02:44:22ZengWolters Kluwer Medknow PublicationsJournal of Advanced Lung Health2772-71652772-71732025-07-015313514010.4103/jalh.jalh_64_24Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern IndiaHindol MondalManasi Basu BanerjeeAbheek DasSomnath MaityIntroduction: Multidrug resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is a leading cause of death in India. To combat this, National TB Elimination Programme, erstwhile RNTCP) has launched “shorter oral bedaquiline (Bdq)-containing MDR/RR-TB regimen” from March 2021 replacing the injectable containing MDR/RR-TB regimen in a phased manner. Objective: We want to measure the outcome and safety profile of this newly introduced shorter oral Bdq-containing MDR/RR-TB regimen.” Materials and Methods: A prospective observational study was conducted to evaluate the effectiveness and adverse drug reaction (ADR) profile of “Shorter oral Bdq-containing regimen.” After getting approval from the ethics committee, all MDR/RR-TB subjects receiving the regimen from MDR-TB clinic of Malda Medical College were included in the study and followed up. Sociodemographic data and treatment outcome details were evaluated. ADRs were evaluated for causality, severity assessment, and management aspects. Result: Of the total, 96 patients were assessed for eligibility. Sixty-three patients were enrolled (n = 63), followed up and analyzed. 19 (30%) patients were cured while 33 (52.4%) patients more had completed treatment. 6 (9.5%) patients declared as treatment failure. One subject died during treatment. Four patients were lost to follow-up (6.4%). In total, 189 ADRs were reported. Commonly observed ADRs were anorexia (60%), nausea (51%), and weakness (46%). Majority were “possible” category by causality assessment and “mild” in severity assessment. Hepatitis was only severe ADR observed. Conclusion: Success rate and adherence observed with this regimen were encouraging. ADRs were mostly mild and managed symptomatically with regular monitoring in some cases.https://journals.lww.com/10.4103/jalh.jalh_64_24adverse eventsbedaquilinemultidrug-resistant/rifampicin-resistant tuberculosis
spellingShingle Hindol Mondal
Manasi Basu Banerjee
Abheek Das
Somnath Maity
Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern India
Journal of Advanced Lung Health
adverse events
bedaquiline
multidrug-resistant/rifampicin-resistant tuberculosis
title Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern India
title_full Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern India
title_fullStr Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern India
title_full_unstemmed Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern India
title_short Efficacy and Adverse Event Profile in Patients Receiving “Shorter Oral Bedaquiline-containing Multidrug-resistant/Rifampicin-resistant Tuberculosis Regimen” in a Tertiary Care Hospital in Eastern India
title_sort efficacy and adverse event profile in patients receiving shorter oral bedaquiline containing multidrug resistant rifampicin resistant tuberculosis regimen in a tertiary care hospital in eastern india
topic adverse events
bedaquiline
multidrug-resistant/rifampicin-resistant tuberculosis
url https://journals.lww.com/10.4103/jalh.jalh_64_24
work_keys_str_mv AT hindolmondal efficacyandadverseeventprofileinpatientsreceivingshorteroralbedaquilinecontainingmultidrugresistantrifampicinresistanttuberculosisregimeninatertiarycarehospitalineasternindia
AT manasibasubanerjee efficacyandadverseeventprofileinpatientsreceivingshorteroralbedaquilinecontainingmultidrugresistantrifampicinresistanttuberculosisregimeninatertiarycarehospitalineasternindia
AT abheekdas efficacyandadverseeventprofileinpatientsreceivingshorteroralbedaquilinecontainingmultidrugresistantrifampicinresistanttuberculosisregimeninatertiarycarehospitalineasternindia
AT somnathmaity efficacyandadverseeventprofileinpatientsreceivingshorteroralbedaquilinecontainingmultidrugresistantrifampicinresistanttuberculosisregimeninatertiarycarehospitalineasternindia